Changes in Cancer Care: Practicing in the Era of COVID-19
A 1-hour enduring broadcast from the NCODA 2020 Fall Summit.
This educational activity includes an archived webcast originally presented at the NCODA Fall Summit on October 22-23, 2020. Information was accurate at the time of the live presentation but may have since become outdated.
This educational activity includes an archived webcast originally presented at the NCODA Fall Summit on October 22-23, 2020. Information was accurate at the time of the live presentation but may have since become outdated.
This activity is sponsored by PTCE and supported by an educational grant from
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Faculty Presenter
David DeRemer, PharmD, BCOP, FCCP, FHOPA
Clinical Associate Professor
Assistant Director Experimental Therapeutics
University of Florida College of Pharmacy
University of Florida Health Cancer Center
Gainesville, Florida
Program Description
The COVID-19 pandemic has impacted patients with cancer in multiple ways. Patients with cancer are at a higher risk for contracting COVID-19, and they are also more likely to experience higher morbidity and mortality. The higher risk and mortality present critical challenges for oncology teams who care for and manage these patients. Several organizations have issued cancer-specific guidance for health care providers during the COVID-19 pandemic, and these recommendations continue to evolve quickly based on growing data and supportive evidence. Oncology care teams’ roles have transformed to meet changing practices and challenges. This program will highlight changes to oncology practice and share opportunities to help improve patient outcomes during the pandemic.
Target audience: Oncology pharmacists and pharmacy technicians
Type of activity: Knowledge
Release date: November 6, 2020
Expiration date: November 6, 2021
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Recognize the impact that COVID-19 has had on the treatment and management of patients with cancer
- Discuss the evolving guidelines and recommendations for cancer treatment during the COVID-19 pandemic
- Outline strategies for the oncology care team that improve disease- and treatment-related management in patients with cancer during the COVID-19 pandemic
At the completion of this activity, pharmacy technicians will be able to:
- Recognize the impact that COVID-19 has had on the treatment and management of patients with cancer
- Discuss the evolving guidelines and recommendations for cancer treatment during the COVID-19 pandemic
- Identify operational tactics to improve management of patients with cancer during the COVID-19 pandemic
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-20-344-H01-P and 0290-0000-20-344-H01-T. The activity is available for CE credit through November 6, 2021.Physicians’ Education Resource®, LLC, designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians and Nurses seeking credit should visit: https://www.gotoper.com/go/ncodacovid to participate in this activity.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
David DeRemer, PharmD, BCOP, FCCP, FHOPA, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Brianna Schauer, MBA, PMP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
Physicians’ Education Resource®, LLC
Planning Staff: The staff of Physicians’ Education Resource®, LLC has no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here